| ACLARIS THERAPEUTICS DL 1 |
| USA |
| Gesundheit |
| US00461U1051 / A1412H |
| 8AT (Frankfurt) / ACRS (NASDAQ) |
| FRA:8AT, ETR:8AT, 8AT:GR, NASDAQ:ACRS |
| - |
| https://www.aclaristx.com.. |
|
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United State..
>Volltext.. |
| 381.22 Mio. EUR |
| 306.52 Mio. EUR |
| 6.76 Mio. EUR |
| -63.24 Mio. EUR |
| -56.07 Mio. EUR |
| -0.46 EUR |
| 1.83 Mio. EUR |
| 17.24 Mio. EUR |
| -40.69 Mio. EUR |
| 3.17 |
| -63.15% |
| 56.67% |
| - |
| - |
| - |
| - |
| ACLARIS |
| 20.03.26 |
|